Tumor necrosis factor receptor-associated factor 6 (TRAF6) (TRAF6)

Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a pivotal adapter protein and E3 ubiquitin ligase that bridges the TNF receptor superfamily, Toll-like receptors (TLRs), and Interleukin-1 receptors (IL-1Rs) to downstream signaling pathways (UniProt: Q9Y4K3). It plays a central role in the activation of NF-kappaB and mitogen-activated protein kinases (MAPKs), which are essential for innate and adaptive immune responses, as well as bone metabolism through osteoclast differentiation (NCBI Gene: 7189). Dysregulation of TRAF6 is strongly associated with the pathogenesis of chronic inflammatory conditions, autoimmune diseases, and various malignancies where it promotes cell survival and proliferation (PubMed: 28848233). In the context of drug development, TRAF6 is targeted via small molecules like C25-140 that inhibit its ligase activity or disrupt its interaction with signaling partners like Ubc13 (PubMed: 28213386). Additionally, targeting TRAF6 mRNA using antisense oligonucleotides or siRNA is an emerging strategy to reduce its expression in specific disease states (PubMed: 31558664). While promising, therapeutic intervention must carefully manage the risk of broad immune suppression and disruptions to normal physiological processes like bone homeostasis (PubMed: 10360576).

Other names

Tumor necrosis factor receptor-associated factor 6TNF receptor-associated factor 6E3 ubiquitin-protein ligase TRAF6RNF85RING finger protein 85Interleukin-1 receptor-associated factorTumor necrosis factor receptor-associated factor 6 mRNA

Inhibition of E3 ubiquitin ligase activity via the RING domain, disruption of protein-protein interactions with upstream receptors (e.g., CD40, RANK) or downstream adapters (e.g., Ubc13), and degradation of mRNA transcripts to prevent protein translation (PubMed: 28213386, PubMed: 31558664).